Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61248 | 0.79 | KDM1A (0.36) | CYP19A1CYP11B1CYP11B2DRD2DRD4 | |
| SCHEMBL9222380 | 0.79 | DRD2 (0.33) | CYP19A1CYP11B1CYP11B2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL9099409 | 0.77 | KDM1A (0.35) | CYP11B1CYP11B2DRD2DRD4 | |
| SCHEMBL1949050 | 0.76 | DRD2 (0.32) | CYP11B1CYP11B2DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL8762469 | 0.70 | CYP19A1 (0.37) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL8572177 | 0.66 | — | — | |
| SCHEMBL7204963 | 0.64 | KDM1A (0.38) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL7602772 | 0.64 | HTR2A (0.31) | — | |
| SCHEMBL5354270 | 0.64 | — | — | |
| SCHEMBL7053434 | 0.61 | CHRNA7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20110137060-A1 | PREPARATION OF ANSA METALLOCENE COMPOUNDS | BASELL POLYOLEFIN GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| EP-2328906-A1 | PREPARATION OF ANSA METALLOCENE COMPOUNDS | Basell Polyolefine GmbH (DE) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010022878-A1 | PREPARATION OF ANSA METALLOCENE COMPOUNDS | BASELL POLYOLEFINE GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
| EP-0283164-B1 | Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers | MITSUI PETROCHEMICAL IND (JP) | 1995-05-24 | — | — | EP | disclosed |
| US-5008356-A | Copolymerization using coordination catalysts | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-04-16 | — | — | US | disclosed |
| US-5003019-A | Radiation transparent, heat resistant, solvent resistant copolymer | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-26 | — | — | US | disclosed |
| EP-0283164-A2 | Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | CYP19A1 3735/4885CYP11B1 3606/4885CYP11B2 3693/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | CYP19A1 3735/4885CYP11B1 3606/4885CYP11B2 3693/4885 |
| US-20110137060-A1 | PREPARATION OF ANSA METALLOCENE COMPOUNDS | NCL, ARSA, NASP | CYP19A1 1504/4885CYP11B1 1789/4885CYP11B2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.